Barchart on MSN9h
How Is Gilead Sciences' Stock Performance Compared to Other Pharmaceutical Stocks?
Valued at a market cap of $143.8 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, ...
The Japan Times19h
Gilead's Japan head says nation can be among first to end HIV epidemic
The pharmaceutical powerhouse has two drugs that disrupt the transmission of the virus, one of which has been approved for ...
Zacks Investment Research on MSN1d
Gilead Sciences, Inc. (GILD) Hits Fresh High: Is There Still Room to Run?
Shares have been on the move with the stock up 17.1% over the past month. The stock hit a new 52-week high of $117.39 in the previous session. Gilead Sciences has gained 24.2% since the start of the ...
Fierce Pharma2d
Gilead sets aside $200M for potential settlement over HIV drug speaker program
Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...
Gilead Sciences sets aside $200 million to resolve HIV drug probe
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
Oppenheimer Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price
Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report ...
Gilead price target raised to $126 from $116 at BofA
BofA raised the firm’s price target on Gilead (GILD) to $126 from $116 and keeps a Buy rating on the shares. For the last several weeks, ...
Gilead price target raised to $132 from $115 at Oppenheimer
Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...